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Receptor activator of nuclear factor kappa-B ligand (RANKL) is an essential mediator of osteoclast for-
mation, function and survival. In patients with solid tumor metastasis to the bone, targeting the bone
microenvironment by inhibition of RANKL using denosumab, a fully human monoclonal antibody (mAb)
speciﬁc to RANKL, has been demonstrated to prevent tumor-induced osteolysis and subsequent skeletal
complications. Recently, a prominent functional role for the RANKL pathway has emerged in the primary
bone tumor giant cell tumor of bone (GCTB). Expression of both RANKL and RANK is extremely high in
GCTB tumors and denosumab treatment was associated with tumor regression and reduced tumor-as-
sociated bone lysis in GCTB patients. In order to address the potential role of the RANKL pathway in
another primary bone tumor, this study assessed human RANKL and RANK expression in human primary
osteosarcoma (OS) using speciﬁc mAbs, validated and optimized for immunohistochemistry (IHC) or ﬂow
cytometry.
Our results demonstrate RANKL expression was observed in the tumor element in 68% of human OS
using IHC. However, the staining intensity was relatively low and only 37% (29/79) of samples ex-
hibitedZ10% RANKL positive tumor cells. RANK expression was not observed in OS tumor cells. In
contrast, RANK expression was clearly observed in other cells within OS samples, including the myeloid
osteoclast precursor compartment, osteoclasts and in giant osteoclast cells. The intensity and frequency
of RANKL and RANK staining in OS samples were substantially less than that observed in GCTB samples.
The observation that RANKL is expressed in OS cells themselves suggests that these tumors may mediate
an osteoclastic response, and anti-RANKL therapy may potentially be protective against bone pathologies
in OS. However, the absence of RANK expression in primary human OS cells suggests that any autocrine
RANKL/RANK signaling in human OS tumor cells is not operative, and anti-RANKL therapy would not
directly affect the tumor.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteosarcoma (OS) is the most common primary malignant tu-
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all).deposition by the malignant mesenchymal cells [1]. In OS, current
evidence supports an osteoblastic population as the cell of origin [2],
although the distinct histological subtypes (e.g. osteoblastic, ﬁbro-
blastic, chondroblastic and telangiectactic) indicate potential for
heterogeneous origins. In association with varying degrees of bone
matrix deposition, OS is characterized by local bone destruction and
frequent lung metastasis. Ten-year survival outcomes for patients
with localized OS are approximately 65% and outcomes, along with
the standard medical treatment, have not changed substantially in
recent years. Patients with recurrent OS have a poor prognosis and
there is great desire to develop improved therapies [3].
In solid tumors which have metastasized to bone or in giant
cell tumor of bone (GCTB), lytic bone destruction is mediated by
osteoclasts. Osteoclasts are highly specialized cells derived from
the monocyte/macrophage lineage necessary for the degradationicle under the CC BY-NC-ND license
AB C
Fig. 1. huRANKL antibody validation for IHC methods. (A) Anti-huRANKL mAb M366 IHC reveals speciﬁc signal in mouse L929 cells transduced with huRANKL cDNA (L929
huRANKL), but not parental L929 cells (L929 control). (B) Similarly, analysis of dissociated proteins on western blot using mAb 366 of L929 huRANKL cells detected a protein
of approximately 45 kDa, the predicted size for full-length human RANKL [28]. Positions of molecular weight markers are illustrated on left (kDa). (C) Determination of
RANKL cell surface protein expression on L929 cells was performed using ﬂow cytometry. Expression of RANKL was detected using the M366 mAb and a goat antimouse
secondary antibody conjugated to APC. M366 staining on huRANKL transduced L929 cells is indicated with the red line and on parental L929 cells (L929 control) a solid black
line. The M366 anti-huRANKL antibody detects a signal by IHC, western blot, and ﬂow cytometry speciﬁcally in L929 cells transduced with huRANKL and not parental L929
cells. APC, allophycocyanin; cDNA, complementary deoxyribonucleic acid; IHC, immunohistochemistry; mAb, monoclonal antibody; RANKL, receptor activator of nuclear
factor kappa-B ligand.
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of nuclear factor kappa-B ligand (RANKL), a tumor necrosis factor
ligand superfamily member, is essential for the formation, acti-
vation, and function of osteoclasts. RANKL is expressed by cells of
the osteoblast lineage in the bone stroma as well as osteocytes and
acts via a paracrine mechanism, binding to its cognate receptor
RANK expressed on osteoclasts and osteoclast precursors [4]. De-
nosumab, a fully human monoclonal antibody (mAb) speciﬁc to
RANKL, inhibits osteoclastogenesis and osteoclast-mediated bone
destruction. In clinical studies, denosumab reduced tumor-in-
duced bone resorption and skeletal complications of metastatic
bone disease [5–7], including delaying the development of bone
metastasis in men with castrate-resistant prostate cancer [8,9].
Osteoclasts have been observed in OS at sites of bone resorp-
tion, either at the tumor/bone interface or within the tumor tissue
at sites of neoplastic osteoid [10]. Cortical destruction and exten-
sion of the tumor mass into the soft tissue is frequently evident in
OS patients, suggesting involvement of osteoclasts in associated
bone pathologies. The human OS cell line SaOS-2 has been shown
to support osteoclastogenesis via RANKL production on the surfaceof OS cells [11] and RANKL expression has been reported on pri-
mary feline, canine [12], and human OS cells [13] with variable
frequency. In preclinical studies, animal models of OS have also
indicated that RANKL levels increase in tumor-involved bone
[14,15]. Pharmacologic inhibition of RANKL has been shown to
prevent increased osteolysis, reduce skeletal tumor growth and
reduce lung metastases (often associated with an increased sur-
vival) in these models [16–18]. Osteoclast inhibition, achieved with
either RANKL blockade or bisphosphonates, results in similar an-
titumor and bone-protective effects in these models [19]. These
studies support the notion that RANKL, produced within the re-
active bone stroma and potentially within OS cells themselves,
contributes to OS-mediated bone degradation/lysis. In addition to
potential alterations in RANKL in OS, RANK expression has been
reported in mouse and human OS cell lines [20,21] and in primary
human OS [20,22]. The prevalence of RANKL and RANK expression,
as well as any associated prognostic signiﬁcance, varies con-
siderably in these published reports of human OS.
In a recent characterization of another primary bone tumor,
GCTB, we and others have conﬁrmed signiﬁcant RANKL expression
Fig. 2. RANKL and RANK IHC of GCTB. IHC performed on FFPE section of GCTB,
which serves as an internal positive and negative control since RANKL and RANK
are expressed in distinct compartments [25]. GCTB is composed of osteoclast-like
giant cells and myeloid giant cell precursors that express RANK and stromal tumor
cells that express RANKL. (A) The RANKL IHC using M366 clearly indicates stromal
tumor cells but is excluded from the giant cell component. (B) Conversely, the
RANK IHC using N-2B10 recognizes giant cells and myeloid osteoclast precursors
but is excluded from the stromal compartment. FFPE, formalin-ﬁxed, parafﬁn-
embedded; GCTB, giant cell tumor of bone; IHC, immunohistochemistry; RANK,
receptor activator of nuclear factor kappa-B; RANKL, RANK ligand.
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myeloid-derived giant cell component [23]. In patients with re-
current or unresectable GCTB, treatment with denosumab, was
associated with tumor regression and reduced tumor-associated
bone lysis [24,25]. The objective of the present study was to as-
certain human RANKL and RANK protein expression in primary
human OS using speciﬁc mAbs validated and optimized for im-
munohistochemistry (IHC).2. Materials and methods
2.1. Tissue samples
Osteosarcoma tissue microarrays (1.5 mm [diameter] cores)
were obtained from US Biomax (Rockville, MD). Large tissue sec-
tions (slides; 20 mm [diameter] cores) from anonymized OS
samples were obtained from Asterand (Detroit, MI) and processedat the Amgen Tissue Bank. One limitation of the present study is
the degree of chemotherapy pretreatment prior to sample acqui-
sition or other sampling preparation variables, such as time to
sample ﬁxation, are unknown. Any effect of these variables on
RANK or RANKL IHC performance is unknown.
2.2. Cell lines and expression analyses
The human cancer cell lines H1299 and COLO205 were obtained
from the American Type Culture Collection (ATCC) and cultured in
Roswell Park Memorial Institute media supplemented with 10%
fetal bovine serum (FBS), penicillin, streptomycin, and glutamine
(Invitrogen). These cells are subsequently referred to as H1299-
parental cells and COLO205-parental cells. The human cancer cell
lines Karpas, H929, and Ramos were also obtained from ATCC and
cultured as described above. Parental cells were then transduced
with a retroviral LZRS-pBMNZ vector containing a full-length ver-
sion of the RANK. Surface expression of RANK was conﬁrmed by
ﬂow cytometry analysis using mAbs against human RANK (Amgen
mAbs N-2B10, N-1H8, and M331) and a goat, antimouse secondary
antibody conjugated to APC. Retroviral transduction methods and
the generation of MDA-231-parental and MDA-231-RANK cells are
described in Blake et al. [26]. Tumor xenografts were generated in
female athymic (R-Foxn1onu4) nude mice [26].
For RANK mRNA expression analysis, total RNA was isolated
from tumor cell lines using the RNAeasy™ Kit (Qiagen, Valencia,
CA) and transcribed into cDNA using random hexamer priming
and TaqMan™ Reverse Transcription Reagents (Applied Biosys-
tems, Inc., Foster City, CA). Ten nanograms of tumor cell cDNA was
analyzed for RANK expression using Assay on Demand™ primer
probe set Hs00187189_m1 (Applied Biosystems, Inc.). Quantitative
real-time reverse transcriptase polymerase chain reaction (RT-
PCR) was performed using the ABI Prisms 7900HT Sequence De-
tection System (Applied Biosystems, Inc.). Gene expression was
calculated relative to β-actin expression (control) and reactions
were performed in triplicate. Surface expression of RANK and
RANKL was determined by ﬂow cytometry after incubation with
either 1 mg/ml of mouse anti-RANK antibody (clones N-1H8,
N-2B10, or M331 as indicated), 20 mg/mL mouse anti-human
RANKL antibody M366 (Amgen Inc.) or isotype control (BD Bios-
ciences) in 2% FBS followed by APC-conjugated anti-mouse sec-
ondary antibody. Fluorescence was assessed using a FACScan sor-
ter (BD Biosciences). For RANK surface antigen density measure-
ment, the quantitative indirect immunoﬂuorescence kit (QIFIkit,
Dako, Denmark) using anti-RANK mAb N1-H8 was performed as
described [27]. For Western blotting of huRANKL, cells were lysed
in K-Lysis buffer (Cell Signaling Technology), total protein quanti-
ﬁed using BCA (Thermo Scientiﬁc), and analyzed using SDS-PAGE
and mAb M366, as described in Blake, 2014. For in situ hy-
bridization (ISH) of huRANKL, antisense and sense control tran-
scripts were radiolabeled and synthesized with 33P-UTP (Amer-
sham; labeling isotope) as described [28]. Slides were counter-
stained with hematoxylin and eosin (H & E) and imaged using light
and darkﬁeld illumination. For IHC of L929 cells (parental or
transfected with human RANKL cDNA), cells were embedded in
collaplugs, formalin-ﬁxed and parafﬁn embedded. Four microns
sections were cut and antigen retrieval was performed in a pres-
sure cooker via citra buffer prior to staining with 3 mg/mL of M366.
Slides were developed using Romulin AEC (Biocare).
2.3. Generation and optimization of anti-huRANK and anti-huRANKL
mAbs for IHC
A soluble form of the extracellular huRANK (amino acids 1 to
213 including the signal sequence) was fused to the Fc portion of
human immunoglobulin G1 (IgG1). The fusion protein was
A B
Fig. 3. huRANK antibody validation for IHC methods. (A) RANK IHC was performed on FFPE samples of xenografts of the speciﬁed human cancer cells. Parental cells did not
detectably express RANK as conﬁrmed by multiple independent methods. There was no detectable signal with the isotype control antibody. Both antibodies against huRANK
(N-1H8 and N-2B10) provide a similar staining pattern, essentially cross-validating one another. (B) The same cells used for the above tumor xenografts were grown in vitro
and processed for ﬂow cytometry. For anti-RANK staining, the pattern of staining by both test antibodies N-1H8 and N-2B10 was compared with a previously identiﬁed mAb
(M331) useful for ﬂow cytometry applications (Armstrong [31]). Solid grey line: Unstained; Red line: Secondary control¼Goat antimouse APC; Blue line: Isotype control 4D2
(anti-AGP3 muIgG1), 1 μg/mL; Purple line: M331 (anti-huRANK muIgG1), 1 μg/mL; Green line: N-1H8 (anti-huRANK muIgG1), 1 μg/mL; Black line: N-2B10 (anti-huRANK
muIgG1), 1 μg/mL. The RANK signal by IHC is concordant with the signal by ﬂow cytometry. APC, allophycocyanin; FFPE, formalin-ﬁxed, parafﬁn-embedded; IHC, im-
munohistochemistry; mAb, monoclonal antibody; RANK, receptor activator of nuclear factor kappa-B.
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standard techniques [29]. Recombinant RANK-Fc was emulsiﬁed in
Complete Freund’s Adjuvant (Pierce™) and immunized into Balb/c
and 129xBL/6 F1 mice (The Jackson Laboratory™). Second and
third immunizations were performed at 3-week intervals using
the huRANK-antigens suspended in RIBI adjuvant (Sigma™). Ten
days following the third immunization, blood samples were col-
lected. Serum and hybridoma supernatants were screened for
RANK-Fc binding by ELISA and the top 96 mAbs were expanded in
culture and the supernatants collected for puriﬁcation. Eighty IgGs
were tested on FFPE control sections including positive and ne-
gative control tumor xenografts (H1299-parental and H1299-
RANK) and clinical GCTB samples according to methods as sum-
marized below. Nine of 80 IgGs speciﬁcally stained the FFPE po-
sitive control xenografts (H1299-RANK) and GCTB osteoclasts
without any detectable staining to negative controls (H1299-par-
ental xenografts). From this pool of nine mAbs, binding to mem-
brane expressed huRANK was conﬁrmed by FACS using the
MDA-MB-231-ATCC LUCI-parental and the MDA-MB-231-ATCC
LUCI-RANK cell lines described [30]. Anti-RANK mAbs which de-
monstrated speciﬁc binding to surface RANK were then epitope
binned according to antibody competition ELISA. Two candidate
antibodies (N-1H8 and N-2B10) were selected as they representeddistinct epitope binning characteristics (as deﬁned by antibody
competition ELISA) and were conﬁrmed to bind RANK by western
blots, performed as described [26]. Speciﬁcity of anti-RANK mAbs
N-1H8 and N-2B10 was conﬁrmed by positive IHC staining to an
additional positive control, FFPE xenograft tissue (COLO205-RANK)
and negative IHC staining to multiple negative controls, FFPE xe-
nograft tissues (COLO205-parental, Karpas, H929, and Ramos). The
speciﬁc staining pattern observed with both N-1H8 and N-2B10 by
IHC correlated with the detection of surface RANK by ﬂow cyto-
metry using the same antibodies. Finally, the positive and negative
expression patterns revealed by N-1H8 and N-2B10 on IHC and
ﬂow cytometry on multiple positive (H1299-RANK, COLO205-
RANK) and negative controls (H1299-parental and COLO205-par-
ental) were concordant with the ﬂow cytometry pattern for a
distinct anti-huRANK mAb (M331) [31]. The anti-huRANKL mAb
M366 has been described previously [23].
IHC analysis was carried out on FFPE samples using automated
staining and optimized methods as described [23]. To assess ex-
pression for each analyte within tumor cells, the H-score approach
was used. Brieﬂy, percent of immunostained tumor cells and
staining intensity, 0 (negative), 1þ (weak), 2þ (moderate) and 3þ
(strong) were scored; an H-score was calculated using the fol-
lowing formula: H-score¼(percentage of cells of weak1)þ
Table 1
Patient characteristics.
Age (years) Range 11–64
Mean 32.1
Median 32
Sex; n (%) Male 36 (64%)
Female 20 (36%)
Site of primary tumor; n (%) Femur 24 (43%)
Tibia 6 (11%)
Humerus 7 (13%)
Rib/scapula 5 (9%)
Other/unidentiﬁed bone site 14 (25%)
Stage; n (%) IA 7 (12%)
IB 4 (7%)
IIA 14 (25%)
IIB 22 (39%)
III 3 (5%)
IV 5 (9%)
Unidentiﬁed 1 (2%)
Analysis of RANKL and RANK was determined within distinct compartments, in-
cluding tumor tissue, inﬁltrating cells, and adjacent normal bone tissue when
present. The H-score distributions for RANKL or RANK selectively within OS tumor
cells are shown in Fig. 4. The staining distributions for RANKL or RANK within
normal bone or inﬁltrating (nontumor) cells were noted without quantitative
scoring. OS, osteosarcoma; RANK, receptor activator of nuclear factor kappa-B;
RANKL, RANK ligand.
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strong3). The maximum H-score would be 300, corresponding
to 100% of cells with strong intensity (3þ). The staining of RANKL
and RANK within normal bone or inﬁltrating (non-tumor) cells
was determined without quantitative scoring. Microscopic images
were photographed using a Nikon™ Eclipse E600 microscope with
a Nikon™ DXM1200 digital camera. Resulting images were white-
balanced using Adobe™ Photoshop CS software but no additional
image modiﬁcations were employed.3. Results
3.1. Development and optimization of anti-RANKL and anti-RANK
mAbs for IHC applications
Our strategy for substantiating antibody speciﬁcity for both
analytes, RANKL and RANK, was achieved by demonstrating con-
cordant signals between the antibody used for IHC application
with independent expression analyses using multiple methodol-
ogies, as outlined below. For validation and optimization of the
anti-RANKL antibody M366 for IHC applications, speciﬁcity con-
trols were ﬁrst performed in mouse L929 cells and analyzed by
IHC, western blotting and ﬂow cytometry. Upon M366 analysis, a
positive signal for each independent assay was demonstrated in
L929 cells transfected with human RANKL cDNA (L929 huRANKL);
an undetectable signal was observed in untransfected cells (L929-
parental; negative control; Fig. 1).
We also performed IHC on FFPE sections of human lymph node
(LN), a tissue known to express RANKL [28], and demonstrated a
RANKL signal detectable in the draining cortex. The positive IHC
pattern for RANKL overlapped with that using an independent
method (in situ hybridization [ISH]) and conversely, regions of the
LN without a detectable ISH signal for RANKL were also negative
for RANKL staining by IHC (Supplemental Fig. 1). Finally, we uti-
lized GCTB as controls for each RANKL IHC run on test cases, since
GCTB is a complex tissue where RANKL is expressed within the
stromal element of GCTB but excluded from giant osteoclast cells
[23], thus providing an internal positive and negative control for
the RANKL IHC (Fig. 2).The development of anti-RANK mAbs suitable for IHC appli-
cations relied on screening mAbs directly on formalin-ﬁxed tissues
with pre-deﬁned antigen expression, as described in Materials and
methods. Speciﬁcally, we utilized multiple independent methods
(e.g. ﬂow cytometry and RT-PCR) to deﬁne human tumor cell lines
with undetectable RANK expression (negative control; parental
cell lines) and then transfected these cell lines with human RANK
cDNA to create positive control cell lines. In order to mimic the
procedure and tissue preparation used for IHC application of the
antibody in surgical samples, FFPE tissues isolated from tumor
xenografts derived from the parental and RANK-transfected cells
grown in mice were used. Positive staining of known, RANK-po-
sitive cells in clinical samples of GCTB was also required for
screening of potential anti-RANK mAbs. In order to proceed to
antibody optimization in IHC, we also demonstrated that candi-
date antibodies had no detectable IHC staining in negative control
tumor xenografts and in RANK-negative cells within GCTB (data
not shown).
After initial screening steps, several anti-RANK mAbs were
identiﬁed which demonstrated reproducible, speciﬁc and selective
staining of human RANK in FFPE tumor tissues. Two high afﬁnity,
anti-RANK mAb candidates (clones N-1H8 and N-2B10), were se-
lected for ﬁnal optimization and represent diverse epitope binding
within the RANK extracellular domain (data not shown). Both
N-1H8 and N-2B10 mAbs demonstrated speciﬁc IHC staining in
FFPE sections from two independent, RANK-transfected tumor
xenografts (H1299-RANK and COLO205-RANK), while FFPE sec-
tions from the negative xenograft controls (untransfected H1299-
parental or COLO205-parental; Fig. 3A) or Karpas, H929 or Ramos
(Supplemental Fig. 2) did not show any RANK staining. Speciﬁcity
and selectivity of RANK IHC staining using N-1H8 or N-2B10 mAb
were further substantiated by the detection of RANK using in-
dependent analyses, including mRNA detection (RT-PCR; Supple-
mental Table 1) and surface protein detection (ﬂow cytometry;
Fig. 3B and Supplemental Fig. 3). As additional tests for speciﬁcity,
we demonstrated that N-1H8 and N-2B10 mAbs revealed the same
pattern of RANK staining on ﬂow cytometry as compared with that
observed with an anti-RANK mAb distinct from those used for IHC
applications (Fig. 3B). RANK staining by IHC was only observed in
xenografts from cells which were shown to be RANK positive by
ﬂow cytometry or by RT-PCR. No RANK IHC signal was detected in
cells which had undetectable RANK levels by RT-PCR or ﬂow cy-
tometry (summarized in Supplemental Table 1).
Demonstration of very speciﬁc RANK IHC staining of osteoclasts
in decalciﬁed FFPE human bone sections (data not shown) pro-
vided an additional conﬁrmation of reagent and method speciﬁ-
city. While IHC positive for RANK staining, the positive controls for
RANK expression (H1299-RANK and COLO205-RANK) expressed
very high levels of protein due to the stable transfection of RANK
cDNA and were not a rigorous test of antibody sensitivity. To ad-
dress sensitivity of RANK IHC with mAbs N-1H8 and N-2B10, we
identiﬁed two breast cancer cell lines (HCC70 and H1954) which
expressed much lower levels of RANK (estimated to express be-
tween 20- and 100-fold lower RANK expression by FACS and RT-
PCR measures [Supplemental Table 1 and Supplemental Fig. 3]);
quantitation of surface protein using a ﬂow cytometry based
method conﬁrmed that these cell lines expressed low levels of
surface RANK expression (18007365 receptors/cell for H1954 and
912072826 receptors/cell for HCC70 cells). Despite these low le-
vels of RANK expression, RANK protein was readily detectable in
FFPE xenograft tissues samples from either HCC70 or H1954 cells
using mAbs N-1H8 or N-2B10 (Supplemental Fig. 4 and summar-
ized in Supplemental Table 1) indicating the sensitivity of this IHC
approach. While both N-1H8 and N-2B10 anti-RANK mAbs gave
identical staining patterns, we proceeded with N-1H8 for most IHC
applications as it had slightly greater sensitivity while retaining
Fig. 4. RANKL and RANK H-score distribution in OS. The H score incorporates intensity (scale of 0–3) and percentage of tumor cells stained positive, giving a range of 0–300.
RANK IHC was performed using N-1H8 mAb on the small core TMA samples and conﬁrmed using N-2B10 mAb on the larger OS tumor sections. RANKL IHC was performed
using M366 mAb on both the TMA and large tissue sections. The H-score distribution for both analytes are depicted for both (A) the small TMA core samples and (B) the
larger tissue sections. IHC, immunohistochemistry; OS, osteosarcoma; RANK, receptor activator of nuclear factor kappa-B; RANKL, RANK ligand.
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3.2. Expression analysis of RANKL and RANK in OS
Expression of RANKL and RANK was determined by IHC in
primary OS samples, including a TMA of small core biopsy speci-
mens (1.5 mm [diameter]) representing 40 individual patients and
also in large tissue sections (20 mm [diameter]) from a smaller
study set (n¼16). Incidence was scored as a positive IHC signal
(any intensity) while the H-score method captured the hetero-
geneity and intensity of IHC signals; the maximum H-score is 300
(Material and methods). The patient characteristics are summar-
ized in Table 1.
There was a wide range of RANKL expression within the OS
tumor cell component of both sample sets examined, with many
samples negative for RANKL expression while other samples had
high levels of RANKL expression (Figs. 4 and 5).
Within the OS TMA, RANKL-positive tumors (any tumor cells
positive) were observed for the majority of samples (65%; 26/40)but the H-scores were typically less than 100 (mean¼23.4).
RANKL expression within OS was not uniformly observed in all
tumor cells and only a few tumor samples (20%; 8/40)
exhibited410% positive OS cells. In large OS tissue sections, the
incidence of RANKL-positive tumors (any tumor cells positive) was
75% (12/16) and H-scores were higher (mean H-score¼73.5) than
the TMA. Fifty percent of large OS tissue sections exhibited410%
cells positive for RANKL. The quantitative and qualitative expres-
sion patterns for RANKL were similar between the two in-
dependent sample sets, with generally higher H-scores for RANKL
observed in the larger tissue sections, as expected given the larger
tissue surface area. The speciﬁcity of the RANKL staining was
supported by the distinct expression within occasional tumor cells
and tumor anaplastic cells adjacent to RANKL-negative osteoclasts
(Fig. 5) as well as the expected positive RANKL expression fre-
quently observed within normal stroma at the bone interface
(Fig. 6A).
Analysis of RANK IHC in the large OS tissue sections and
the small core biopsy specimens did not indicate any substantial
Fig. 5. Range of RANKL protein expression in OS. RANKL IHC performed with mAb M366. Representative IHC images from four separate OS tumor samples are shown. Arrows
indicate RANKL-positive tumor cells and tumor anaplastic cells. In addition, RANKL-negative osteoclasts are also clearly delineated (arrow). The four images demonstrate a
range of RANKL positivity, as indicated by the different H-scores. The H-score for each image was as follows: upper left panel, H-score¼260; upper right panel, H-score¼210;
lower left panel, H-score¼180; lower right panel, H-score¼20. IHC, immunohistochemistry; OS, osteosarcoma; RANK, receptor activator of nuclear factor kappa-B ligand.
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samples from the TMA had RANK staining potentially in OS tumor
cells. In this single case, the faint signal and low percentage of
positive cells precluded a clear distinction between the spindeloid
(somewhat anaplastic) OS cells or the mononucleated myeloid
cells. This is in marked contrast to the high RANK signal observed
within the myeloid osteoclast precursor compartment present in
65% (26/40) of tumors and the obvious RANK staining within any
giant cell osteoclasts embedded in tumor (Fig. 7). Analysis of the
large OS tissue sections was performed with a second anti-RANK
antibody (N-2B10) with a distinct RANK epitope binding
characteristics to conﬁrm the above ﬁndings and demonstrated
similar results, RANK staining within the myeloid osteoclast
precursor compartment and RANK staining within any giant cell
osteoclasts present; no OS tumor cells stained positive for RANK
(see Fig. 4 for summary of H-scores). The ﬁdelity, sensitivity and
speciﬁcity of the staining is supported within any individual tissue
sample by the distinct expression of RANK observed as expected in
normal osteoclasts, either within the tumor mass (Fig. 7) or in
samples where the tumor/bone interface was represented (Fig. 6B),
which contrasts with the absence of signal within OS tumor cells
(Fig. 7).4. Discussion
In the present study, we developed and optimized methodol-
ogies and monoclonal anti-RANK and anti-RANKL antibodies for
IHC applications and expression analysis in human OS. We in-
corporated a number of independent speciﬁcity controls for each
analyte. The positive and negative IHC signal patterns for the anti-
RANKL mAb were very precisely correlated to the western blotting
and ﬂow cytometry signals for the control cells. Moreover, the
speciﬁc pattern of RANKL staining observed by IHC with mAb
M366 overlapped with RANKL in situ mRNA analysis. For the
RANK expression analysis, a concordant expression pattern was
observed using mAbs in IHC on a variety of positive and negative
controls compared with expression analysis tested using other
methods, such as ﬂow cytometry using mAbs which bind RANK
via distinct epitopes and RT-PCR. Each RANKL and RANK IHC test
of OS samples included positive and negative controls, including
clinical GCTB samples. These robust speciﬁcity controls provide
evidence for the reliability of RANKL and RANK expression analysis
reported herein.
Utilizing IHC, the majority of OS samples were positive for
RANKL (68%), with RANKL staining detectable in OS tumor cells
and tumor anaplastic cells. However, a wide range of RANKL ex-
pression within the OS component was observed and many
Fig. 6. RANKL and RANK expression within adjacent bone tissue. RANKL and RANK
IHC performed with mAb N-1H8 and M366, respectively. (A) RANKL-expressing
stroma at bone interface. (B) RANK expression in bone osteoclast. IHC, im-
munohistochemistry; mAb, monoclonal antibody; RANK, receptor activator of nu-
clear factor kappa-B; RANKL, RANK ligand.
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tectable RANKL staining. Clearly RANKL expression was not uni-
formly observed within an OS tumor, as only a few samples (16/56)
demonstrated more than 10% of the tumor cells positive for RANKL
signal. The intensity and frequency of RANKL staining in OS sam-
ples observed in this study were substantially less than that ob-
served in GCTB samples using the same antibody for IHC evalua-
tion [23]. The overall incidence of RANKL staining observed in the
present study of human OS (68%) is similar to that observed by Lee
et al. [34] using a goat polyclonal RANKL antisera (75%) but differs
substantially to the 9% RANKL positivity observed by Bago-Horvath
[22]. The relatively small sample size (n¼56) and limited patient
follow-up data precluded any prognostic association with RANKL
incidence or expression levels in the present study. We conclude
that RANKL is observed in the majority of OS cases although the
fraction of positive tumor cells and staining intensity is generally
very low.
In contrast to the RANKL expression, there was essentially no
RANK expression detected in OS tumor cells using IHC. Only one
OS sample (1.9%, 1/52) demonstrated RANK staining potentially
within OS tumor cells while RANK expression was observed as
expected within myeloid osteoclast precursors, giant cellosteoclasts within a tumor mass, and normal osteoclasts at the
bone/tumor interface whenever these cells were present. In fact,
due to the very faint nature of the RANK staining in this single
sample, it was impossible to clearly distinguish between RANK
positivity within the spindeloid and somewhat anaplastic OS cells
or mononucleated myeloid cells. We conclude that RANK protein
expression is not observed in tumor cells from primary human OS
to any prominent degree.
The absence of RANK expression in OS tumor cells observed in
the present study is in marked contrast to the two reports that
RANK is highly expressed in the majority of primary human OS
[20,22]. Mori et al. (2007) reported RANK expression to be
homogeneously expressed (in 100% of tumor cells) in 57% of OS
biopsy specimenss and Bago-Horvath [22] reported moderate or
strongly positive RANK expression in 69% of OS tumor samples.
Given that the IHC scoring systems used in all studies were not
normalized, one cannot make an unbiased comparison of RANK
expression incidence and intensity levels observed in those two
studies with the current study. However, it is important to point
out distinct features of the present study with the two previously
published studies of RANK expression in human OS to address the
very high incidence observed in those studies. Firstly, both pre-
viously published reports relied on commercially available anti-
RANK antibodies and did not provide any evidence for the speci-
ﬁcity and reproducibility of staining for IHC applications nor
conﬁrmation of RANK expression using independent methods or
reagents. Secondly, the use of mAbs for expression analysis in the
present study avoids the technical pitfalls of run-to-run reprodu-
cibility inherent in polyclonal antibodies. Thirdly, neither pre-
viously-published study documented the expected RANK staining
within normal myeloid cells in the tumor mass or at the bone/
tumor interface within any OS sample to document RANK ex-
pression in the expected cell types and provide context for the
signal to noise for the reagents and methods used. The validation
of the RANK antibodies used for IHC demonstrated concordant
positive (and negative) signals between multiple independent
methodologies and addressed sensitivity down to fewer than 1800
receptors/cell. Furthermore, in our analysis of OS samples, two
independent anti-RANK mAbs, each recognizing distinct epitope
binding sites demonstrated an identical positive and negative
staining pattern, essentially cross-validating one another. Different
alternatively-spliced variants of the human RANK gene have been
described which alter exons 7, 8, or 9 encoding in either the
transmembrane or cytoplasmic regions of RANK [32], potentially
impacting IHC detection. However, the antibodies N-1H8 and
N-2B10 bind to the extracellular portion of RANK common to each
variant, thus the IHC results reported here would be inclusive of
any rare, alternatively-spliced forms. Altogether, these speciﬁcity
and sensitivity controls, along with the observed expression of
RANK in the expected osteoclasts and related cells, substantiates
the observation that OS tumor cells do not express RANK to any
major degree. It would seem likely that technical limitations to
these previously published studies may have accounted for the
reportedly high incidence and high expression levels of RANK
within OS tumors.
Aside from distinct technical approaches used, the well-estab-
lished RANKL and RANK expression patterns in the bone further
substantiates the expression patterns deﬁned in the current study
of OS. RANKL and RANK play major roles in bone metabolism due
to the critical role of this pathway in osteoclastogenesis [4]. That is,
RANK is expressed with the hematopoietic myeloid compartment
contributing to myeloid-derived osteoclasts and their precursors
consistent with the observed compartmentalization of RANK
expression within giant cells, osteoclasts and osteoclast precursors
found within OS samples in the present study. Given that OS
tumors may arise from a mesenchymal-osteoblast origin [1,2], it is
Osteoclast
Anaplastic  Cell
Fig. 7. RANK protein expression in OS is limited to myeloid osteoclasts and osteoclast precursors. RANK IHC performed with mAb N-1H8. Representative IHC images from
four separate OS tumor samples are shown. Upper left panel shows RANK-positive normal osteoclasts at the tumor–bone interface. Upper right panel shows tumor anaplastic
cells were RANK-negative. Lower left panel shows abundant RANK-positive tumor-associated osteoclasts were present within the tumor in some tumors. Lower right panel
shows no RANK-positive cells were present in some tumors. The H-score was zero for all images for RANK. RANK expression was observed in osteoclasts and myeloid
osteoclast precursors in a majority of samples but not in the sarcoma component. IHC, immunohistochemistry; mAb, monoclonal antibody; OS, osteosarcoma; RANK,
receptor activator of nuclear factor kappa-B.
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expression of RANKL in OS tumor cells is perhaps not surprising. In
normal and pathologic bone, RANKL expression is conﬁned to the
cells of the osteoblast lineage, including osteocytes and has also
been observed in certain tumor cells [33]. The observation herein
of RANKL within reactive bone stroma in OS tumors as well as
many OS cells themselves suggests that RANKL may stimulate
osteoclast differentiation and activation potentially via multiple
sources. Molyneux et al. [35] has reported that human and mouse
OS with reduced expression of the gene encoding the regulatory
subunit α (RIa) of PKA have high RANKL levels suggesting that
pathways regulating RANKL expression may be dysfunctional in
some OS. For any RANKL-positive OS, it remains unclear why
RANKL is not expressed uniformly in all OS tumor cells as observed
in the present study, suggesting that perhaps some element of
local regulation observed in normal osteoblast-lineage cells (e.g.
responsiveness to PTH1r) is retained by OS tumor cells.
In mouse models of OS, pharmacologic inhibition of RANKL is
protective against bone destruction and also decreases tumor
burden [18–20]. This is likely related to osteoclast inhibition, as
treatment with bisphosphonates lead to essentially similarresponses [21]. The reduction in skeletal tumor burden observed
with osteoclast inhibitors results from interruption of the vicious
cycle in which decreased osteoclastic bone resorption and sub-
sequent reduction in localized bone matrix and growth factors
indirectly reduces tumor growth and survival. These pharmacol-
ogy observations demonstrating similar anti-tumor activity of bi-
sphosphonates and RANKL inhibitors are consistent with the ab-
sence of RANK on OS tumor cells and a contribution of RANK-
positive osteoclasts associated with OS tumors (this study and
Avnet et al. [10]) to the bone pathologies observed in OS and po-
tential indirect feedback to the skeletal tumor. The observation
that RANKL is expressed in OS cells themselves suggests that these
tumors may mediate an osteoclastic response independently of (or
in addition to) RANKL within the normal or tumor-reactive bone
stroma. However, the absence of RANK expression in OS tumor
cells indicates that an autocrine RANKL/RANK response in human
OS tumor cells is unlikely to be operative. While anti-RANKL
therapy may inﬂuence the bone microenvironment and may be
protective against bone pathologies in OS, the lack of RANK ex-
pression in tumor cells suggests that this approach would not
directly affect the tumor.
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